Corgenix enters US bio-terrorism defence programme:
This article was originally published in Clinica
Immunoassay firm Corgenix Medical has formed a bio-terrorism defence programme to develop a rapid detection system for viral haemorrhagic fevers. The US Centers for Disease Control and Prevention (CDC) classifies viral haemorrhagic fever as a high priority "category A" biological disease due to its risk as a potential agent of bio-terrorism. Denver, Colorado-based Corgenix said it had requested additional funding from the National Institutes of Health (NIH) to help develop the project.